Developer docs
API playgroundTry for free, no card

Search company profiles

Celloram

Full company profile

uuid000csyl

Namestring
Celloram
Websiteurl
celloram.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with a workforce of 11-50 employees. The "preclinical stage" designation strongly indicates a biotechnology or pharmaceutical company engaged in early-stage therapeutic, diagnostic, or platform development prior to first-in-human clinical trials. The company's legal structure, size band, and location are the only firmographic facts documented; no specific therapeutic area, modality (small molecule, biologic, cell therapy, gene therapy, diagnostic), target indication, pipeline candidates, or underlying scientific platform are disclosed in the available source material.

The company's business model, revenue mechanics, and customer base are not described in any source block. The only direct primary-source data attempt—the company website at celloram.com—displayed only a verification/loading page, yielding no substantive corporate disclosures. Consequently, there are no documented products, services, technology descriptions, pricing models, go-to-market motions, customer segments, partnerships, regulatory filings, management team profiles, funding rounds, intellectual property holdings, or strategic milestones available. The source commentary explicitly flags this as a significant data gap. From an investment due-diligence perspective, Celloram presents as a sub-scale, sub-revenue preclinical life-sciences entity with no publicly verifiable technical, commercial, or capital-markets footprint in the current source set.

Source attribution for this description rests on the firmographic block, which is the only source providing structured company facts; all other sources either repeat the same null findings or confirm the verification-page state of the website.

Short descriptiontext

Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with 11-50 employees. No products, technology, therapeutic focus, or pipeline details are disclosed in available source material.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
preclinical research, drug discovery, biotechnology development, life sciences R&D, therapeutic pipeline
Industry1 code
PRIMARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Research
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Celloram is a preclinical-stage company, indicating it is engaged in early-stage life sciences research and development activities prior to clinical trials. Specific product candidates, therapeutic areas, or commercial offerings are not disclosed in the available source material, as the company's website displayed only a verification/loading page with no substantive content.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeDirect peer
Description

Clinical-stage cell-therapy company developing off-the-shelf iPSC-derived NK and T-cell candidates. Comparable to Celloram as a cell-engineering platform biotech, although Fate is significantly more advanced (multiple clinical programs) and more heavily capitalized.

TypeDirect peer
Description

Preclinical-to-clinical iPSC-derived cell therapy company. Direct peer in modality (engineered cell therapy) and stage profile; went public via SPAC in 2021 and is a useful benchmark for capital intensity and timeline for a Celloram-like platform.

TypeDirect peer
Description

Cell therapy and genome-editing company developing allogeneic CAR-T candidates. Comparable to Celloram in combining cell therapy with a core engineering/CRISPR platform, and is at a similar early-clinical inflection point.

TypeDirect peer
Description

Clinical-stage cell therapy company focused on engineered NK cells for autoimmune disease and oncology. Comparable in cell-therapy modality and platform-based approach, although materially more advanced and capitalized.

TypeBroad incumbent
Description

Clinical-stage allogeneic CAR-T leader and one of the largest independent cell-therapy companies. A broad incumbent in the same modality that sets the competitive ceiling and partnership benchmark for smaller preclinical cell-therapy entrants like Celloram.

TypeBroad incumbent
Description

Bayer-owned cell-therapy company developing iPSC-derived cell therapies, notably for Parkinson's disease. A broad incumbent that validates the cell-therapy exit pathway (large-pharma acquisition) relevant to a preclinical cell-therapy platform such as Celloram.

TypeBroad incumbent
Description

Clinical-stage gene- and cell-therapy company with proprietary TALEN-based genome editing used to engineer allogeneic CAR-T cells. A broad incumbent in the engineered cell-therapy space that competes for similar pharma partnerships.

TypeEmerging player
Description

Clinical-stage gene-editing company co-developing Casgevy (exa-cel) with Vertex. Comparable in combining a cell-therapy-adjacent editing platform with pharma partnerships, and useful as a benchmark for cell-engineering platform value creation.

TypeEmerging player
Description

Clinical-stage CRISPR-based gene- and cell-therapy company. Comparable in the cell-engineering platform thesis, though focused on in-vivo gene editing and ex-vivo edited cell therapies for hematological indications.

TypeEmerging player
Description

Clinical-stage base-editing company with a growing cell-therapy footprint. Comparable as a platform biotech that could either remain independent or become a partnership / M&A target — the same strategic options available to a preclinical cell-therapy company such as Celloram.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celloram

Biotechnology Researchcelloram.com

Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with 11-50 employees. No products, technology, therapeutic focus, or pipeline details are disclosed in available source material.

What Celloram does

Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with a workforce of 11-50 employees. The "preclinical stage" designation strongly indicates a biotechnology or pharmaceutical company engaged in early-stage therapeutic, diagnostic, or platform development prior to first-in-human clinical trials. The company's legal structure, size band, and location are the only firmographic facts documented; no specific therapeutic area, modality (small molecule, biologic, cell therapy, gene therapy, diagnostic), target indication, pipeline candidates, or underlying scientific platform are disclosed in the available source material.

The company's business model, revenue mechanics, and customer base are not described in any source block. The only direct primary-source data attempt—the company website at celloram.com—displayed only a verification/loading page, yielding no substantive corporate disclosures. Consequently, there are no documented products, services, technology descriptions, pricing models, go-to-market motions, customer segments, partnerships, regulatory filings, management team profiles, funding rounds, intellectual property holdings, or strategic milestones available. The source commentary explicitly flags this as a significant data gap. From an investment due-diligence perspective, Celloram presents as a sub-scale, sub-revenue preclinical life-sciences entity with no publicly verifiable technical, commercial, or capital-markets footprint in the current source set.

Source attribution for this description rests on the firmographic block, which is the only source providing structured company facts; all other sources either repeat the same null findings or confirm the verification-page state of the website.

Celloram firmographics

Firmographics
Name
Celloram
Website
https://celloram.com
Company type
Private
Founded year
2018
Headcount range
1–10 employees
Short description
Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with 11-50 employees. No products, technology, therapeutic focus, or pipeline details are disclosed in available source material.
Ownership category
akta.pro rank

Celloram industry classification

Industry
Product category
Biotechnology Research
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Preclinical research
  • Drug discovery
  • Biotechnology development
  • Life sciences R&D
  • Therapeutic pipeline

Where Celloram is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Markets served

Celloram business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Celloram product offering

Product offering

Core offering

Celloram is a preclinical-stage company, indicating it is engaged in early-stage life sciences research and development activities prior to clinical trials. Specific product candidates, therapeutic areas, or commercial offerings are not disclosed in the available source material, as the company's website displayed only a verification/loading page with no substantive content.

Differentiator

Problem solved

Functional benefit

Companies that use Celloram

Customer profile

Ideal customer profiles1 record

Celloram technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Celloram competitors and assessment

Company assessment

Direct peers

  • Fate Therapeutics: Clinical-stage cell-therapy company developing off-the-shelf iPSC-derived NK and T-cell candidates. Comparable to Celloram as a cell-engineering platform biotech, although Fate is significantly more advanced (multiple clinical programs) and more heavily capitalized.
  • Century Therapeutics: Preclinical-to-clinical iPSC-derived cell therapy company. Direct peer in modality (engineered cell therapy) and stage profile; went public via SPAC in 2021 and is a useful benchmark for capital intensity and timeline for a Celloram-like platform.
  • Caribou Biosciences: Cell therapy and genome-editing company developing allogeneic CAR-T candidates. Comparable to Celloram in combining cell therapy with a core engineering/CRISPR platform, and is at a similar early-clinical inflection point.
  • Nkarta: Clinical-stage cell therapy company focused on engineered NK cells for autoimmune disease and oncology. Comparable in cell-therapy modality and platform-based approach, although materially more advanced and capitalized.

Broad incumbents

  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T leader and one of the largest independent cell-therapy companies. A broad incumbent in the same modality that sets the competitive ceiling and partnership benchmark for smaller preclinical cell-therapy entrants like Celloram.
  • BlueRock Therapeutics: Bayer-owned cell-therapy company developing iPSC-derived cell therapies, notably for Parkinson's disease. A broad incumbent that validates the cell-therapy exit pathway (large-pharma acquisition) relevant to a preclinical cell-therapy platform such as Celloram.
  • Cellectis: Clinical-stage gene- and cell-therapy company with proprietary TALEN-based genome editing used to engineer allogeneic CAR-T cells. A broad incumbent in the engineered cell-therapy space that competes for similar pharma partnerships.

Emerging players

  • Crispr Therapeutics: Clinical-stage gene-editing company co-developing Casgevy (exa-cel) with Vertex. Comparable in combining a cell-therapy-adjacent editing platform with pharma partnerships, and useful as a benchmark for cell-engineering platform value creation.
  • Editas Medicine: Clinical-stage CRISPR-based gene- and cell-therapy company. Comparable in the cell-engineering platform thesis, though focused on in-vivo gene editing and ex-vivo edited cell therapies for hematological indications.
  • Beam Therapeutics: Clinical-stage base-editing company with a growing cell-therapy footprint. Comparable as a platform biotech that could either remain independent or become a partnership / M&A target — the same strategic options available to a preclinical cell-therapy company such as Celloram.

Market position

Strengths3 records

Weaknesses3 records

Key risks4 records

Key highlights4 records

Customer concentration

Celloram social profiles

Digital presence

Celloram financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celloram leadership team

Management profile

Number of profiles

Celloram funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celloram M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celloram

What does Celloram do?

Celloram is a preclinical-stage company, indicating it is engaged in early-stage life sciences research and development activities prior to clinical trials. Specific product candidates, therapeutic areas, or commercial offerings are not disclosed in the available source material, as the company's website displayed only a verification/loading page with no substantive content.

Is Celloram a public or private company?

Celloram is a private company. It is classified as unknown.

When was Celloram founded?

Celloram was founded in 2018. It employs 1 to 10 people.

Where is Celloram based?

Celloram is headquartered in Cleveland, United States, in the North America region.

Who are Celloram's main competitors?

Direct peers on record are Fate Therapeutics, Century Therapeutics, Caribou Biosciences and Nkarta. Broad incumbents are Allogene Therapeutics, BlueRock Therapeutics and Cellectis. Emerging players are Crispr Therapeutics, Editas Medicine and Beam Therapeutics.

Does Celloram have an API?

No public API is recorded for Celloram.

What industry is Celloram in?

Celloram's product category is Biotechnology Research. Its primary akta.pro industry code is HLAGANAD, Cellomics & High-Content Screening (HCS) Services. Its NAICS code is 541715 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageScientists Turn COVID-19 Immune Memory into a Powerful New Ally Against CancerScientists from Celloram Inc., University Hospitals, and Case Western Reserve University have developed PROTEXI, a novel dendritic cell cancer vaccine platform that leverages pre-existing SARS-CoV-2 immune memory to amplify the body's ability to recognize and destroy tumors, with findings published in Nature Communications. In preclinical models of melanoma, breast cancer, and humanized mouse models, PROTEXI slowed tumor growth, improved survival, and transformed treatment-resistant tumors into more immune-responsive ones, particularly when combined with MedPacto's TGF-β inhibitor vactosertib or immune-checkpoint inhibitors. The team is advancing PROTEXI toward first-in-human clinical trials in patients with sarcoma, representing a potentially paradigm-shifting approach to cancer vaccine design.GlobeNewswireScientists Turn COVID-19 Immune Memory into a Powerful New Ally Against CancerScientists from Celloram Inc., University Hospitals, and Case Western Reserve University have developed PROTEXI, a dendritic cell cancer vaccine platform that leverages pre-existing SARS-CoV-2 immune memory to amplify antitumor immune responses, with findings published in Nature Communications on July 27, 2026. In multiple preclinical models of melanoma, breast cancer, and humanized mouse models, PROTEXI significantly reduced tumor burden, improved survival, and worked synergistically with MedPacto's TGF-β inhibitor vactosertib and anti-PD-1 checkpoint inhibitors. The research team is now advancing PROTEXI toward first-in-human clinical trials in patients with sarcoma.BioSpaceScientists Turn COVID-19 Immune Memory into a Powerful New Ally Against CancerScientists developed PROTEXI, a dendritic cell vaccine that harnesses pre-existing SARS-CoV-2 immune memory to boost antitumor responses. In preclinical models, it slowed tumor growth and improved survival in melanoma and breast cancer. The platform is advancing to first-in-human trials for sarcoma.PR NewswireCleveland-based Biotech Celloram Inc. Strikes Landmark Licensing Deal with French Biotech GENFIT to Propel its lead asset CLM-022 in Liver Disease TreatmentCelloram Inc., a Cleveland-based biotech startup developing novel medicines for cancer and immune disorders, has entered into an exclusive global licensing agreement with French biotech company GENFIT SA to advance Celloram's first-in-class inflammasome inhibitor CLM-022 for liver disease indications. Under the terms of the agreement, GENFIT will gain access to Celloram's scientists and medicinal chemistry expertise as it works toward securing an IND for future clinical trials. Celloram is eligible to receive up to €160 million in clinical, regulatory, and commercial milestone payments, and is also preparing to launch a Series A funding round in the coming months.